An increase of about 110.35% to Rs. 546.81 millions in the total revenue was observed for the quarter ended March 2026. The total revenue was pegged at Rs. 259.95 millions during the similar quarter previous year.A slim rise of 23.36% was recorded in the Net profit for the quarter ended March 2026 to Rs. 29.73 millions From Rs. 24.10 millions.OP of the company witnessed a marginal growth to 58.54 millions from 41.26 millions in the same quarter last year.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	546.81	259.95	110.35	1788.46	1514.63	18.08	1788.46	1514.63	18.08
Other Income	17.26	52.20	-66.93	31.04	62.25	-50.14	31.04	62.25	-50.14
PBIDT	58.54	41.26	41.88	213.90	227.83	-6.11	213.90	227.83	-6.11
Interest	5.99	6.23	-3.85	27.84	30.45	-8.57	27.84	30.45	-8.57
PBDT	52.55	35.03	50.01	186.06	197.38	-5.74	186.06	197.38	-5.74
Depreciation	17.25	4.66	270.17	70.59	69.62	1.39	70.59	69.62	1.39
PBT	35.30	30.37	16.23	115.47	127.76	-9.62	115.47	127.76	-9.62
TAX	5.57	6.27	-11.16	21.39	33.27	-35.71	21.39	33.27	-35.71
Deferred Tax	-0.95	-0.99	-4.04	-4.09	-3.12	31.09	-4.09	-3.12	31.09
PAT	29.73	24.10	23.36	94.08	94.49	-0.43	94.08	94.49	-0.43
Equity	135.63	127.15	6.67	135.63	127.15	6.67	135.63	127.15	6.67
PBIDTM(%)	10.71	15.87	-32.55	11.96	15.04	-20.49	11.96	15.04	-20.49

Medicamen Biotech Ltd.